Friday, February 8, 2013

Codon AG submits application for approval for the articular cartilage product chondrosphere

co.don® AG has submitted its application for EU marketing authorisation for the articular cartilage product chondrosphere® to the relevant committee of the European Medicines Agency in London.
co.don® AG has successfully obtained a positive opinion from the European Medicines Agency for co.don chondrosphere®. co.don chondrosphere® is used to treat cartilage defects. Its active ingredient consists of spheroids of human autologous matrix-associated chondrocytes.

About co.don® AG:
The company is based in Teltow, Brandenburg, and was founded in 1993. Since 2001 the biopharmaceutical specialist has been listed on the Frankfurt Stock Exchange (ISIN: DE000A1K0227). co.don AG® uses tissue engineering - the cultivation and growth of autologous tissue cells - to develop innovative products and therapeutic concepts for the orthopaedic and neurosurgical markets. The cell-based biological drugs (autologous cell transplants for articular cartilage and intervertebral disks) are produced without the use of antibiotics, growth factors and genetic engineering. The Executive Board of co.don® AG is made up of Dr Andreas Baltrusch (CEO) and Vilma Siodla (COO, CSO).





Enter your email address:


Delivered by FeedBurner